Researchers have found that ZIKV immunity might be shorter-lived than previously thought, which may contribute to local ZIKV resurgence once individual immune responses wane sufficiently to reduce community protective immunity in addition to birth and migration.

15th June 2020 • comment

The remarkable efficacy of the ClearColi BL21(DE3)-based expression system at eliciting the rapid production of specific anti-ZIKV antibodies endorses an innovative method, which can be extended to emerging viruses for which development of immunological tools is an urgent prerequisite.

12th October 2017 • comment